A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (CAPTURE)

Bayer

Status: Completed

Conditions: Hypertension, Pulmonary

Treatments: Drug: Riociguat (Adempas, BAY63-2521)

Study type: Observational

Funder types: Industry

Identifiers

NCT02545465

AD1501 (Other Identifier)

17983

Details and patient eligibility

About

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.

In addition, this study will describe patient demographics and reason for switching

Enrollment: 125 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas

Exclusion criteria

• Patients participating in an investigational program with interventions outside of routine clinical practice
• Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy

Trial design

125 participants in 1 patient group

BAY63-2521

Description:

Patients who have been switched from a Pulmonary Hypertension treatment to Adempas

Treatment:

Drug: Riociguat (Adempas, BAY63-2521)